Stryker's (SYK) Q1 Earnings Beat Estimates, Guidance Raised

Like
Comment
Favorite

Stryker's (SYK) Q1 Earnings Beat Estimates, Guidance Raised

Zacks05-01

Stryker Corporation SYK reported first-quarter 2024 adjusted earnings per share (EPS) of $2.50, which beat the Zacks Consensus Estimate of $2.35 by 6.4%. The bottom line also improved 16.8% year over ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

nomadic_m
·05-02
$Stryker(SYK)$ beats estimates but plunged. next time pls don't schedule earnings +-1 day before Powell's speeches. his words alone can shoot down a dragon 🐲
Reply
2
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2432506451?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1VKaor.8d9bYcvO1nyOeow--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f6206b1433a2040570d7364e7915d0b5","is_english":true,"pubTime":"2024-05-01 21:13","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2432506451","market":"us","top_or_hot":-1,"title":"Stryker's (SYK) Q1 Earnings Beat Estimates, Guidance Raised","media":"Zacks","content":"<div>\n<p>Stryker Corporation SYK reported first-quarter 2024 adjusted earnings per share (EPS) of $2.50, which beat the Zacks Consensus Estimate of $2.35 by 6.4%. The bottom line also improved 16.8% year over ...</p>\n\n<a href=\"https://finance.yahoo.com/news/strykers-syk-q1-earnings-beat-131300980.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stryker's (SYK) Q1 Earnings Beat Estimates, Guidance Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStryker's (SYK) Q1 Earnings Beat Estimates, Guidance Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-01 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/strykers-syk-q1-earnings-beat-131300980.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stryker Corporation SYK reported first-quarter 2024 adjusted earnings per share (EPS) of $2.50, which beat the Zacks Consensus Estimate of $2.35 by 6.4%. The bottom line also improved 16.8% year over ...</p>\n\n<a href=\"https://finance.yahoo.com/news/strykers-syk-q1-earnings-beat-131300980.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SYK","symbol_name":"史赛克","start_time":0,"source_url":"https://finance.yahoo.com/news/strykers-syk-q1-earnings-beat-131300980.html","article_id":"2432506451","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1VKaor.8d9bYcvO1nyOeow--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f6206b1433a2040570d7364e7915d0b5"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2432506451","pubTimestamp":1714569180,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Stryker Corporation SYK reported first-quarter 2024 adjusted earnings per share  of $2.50, which beat the Zacks Consensus Estimate of $2.35 by 6.4%. The bottom line also improved 16.8% year over year.GAAP EPS was $2.05, up 33.1% from the year-ago quarter’s level.SYK’s shares have risen 19.5% year to date compared with the industry's growth of 6.7%. The S&P 500 Index has increased 10.1% in the same period.Revenues totaled $5.24 billion, which beat the Zacks Consensus Estimate of $5.05 billion by 3.7%. The top line also improved 9.7% on a year-over-year basis and 10.2% at constant currency .Revenues in the United States amounted to $3.91 billion, up 11.4% from the prior-year quarter’s reported actuals. International sales increased to $1.33 billion and grew 4.9% year over year reportedly. The figure also rose 6.8%, excluding the negative impact of currency.MedSurg and Neurotechnology: This segment reported sales of $3 billion, up 11.5% year over year and 12.0% at cc. Sales growth was dri","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SYK":"史赛克"},"translate_title":"史赛克（SYK）第一季度盈利超出预期，指引上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SYK":1},"content_text":"Stryker Corporation SYK reported first-quarter 2024 adjusted earnings per share (EPS) of $2.50, which beat the Zacks Consensus Estimate of $2.35 by 6.4%. The bottom line also improved 16.8% year over year.\nGAAP EPS was $2.05, up 33.1% from the year-ago quarter’s level.\nPrice Performance\nSYK’s shares have risen 19.5% year to date compared with the industry's growth of 6.7%. The S&P 500 Index has increased 10.1% in the same period.\nImage Source: Zacks Investment Research\nRevenue Details\nRevenues totaled $5.24 billion, which beat the Zacks Consensus Estimate of $5.05 billion by 3.7%. The top line also improved 9.7% on a year-over-year basis and 10.2% at constant currency (cc).\nRevenues by Geography\nRevenues in the United States amounted to $3.91 billion, up 11.4% from the prior-year quarter’s reported actuals. International sales increased to $1.33 billion and grew 4.9% year over year reportedly. The figure also rose 6.8%, excluding the negative impact of currency.\nSegmental Analysis\nMedSurg and Neurotechnology: This segment reported sales of $3 billion, up 11.5% year over year and 12.0% at cc. Sales growth was driven by increased unit volume as well as higher prices.\nOrthopedics and Spine: Sales in the segment amounted to $2.24 billion, up 7.5% year over year and 8% at cc. This growth was driven by increased unit volume, partially offset by lower prices.\nMargins\nAdjusted gross profit totaled $3.34 billion in the reported quarter, up 10.6% from the year-ago quarter’s level. Adjusted gross margin was 63.6%, up 40 basis points (bps).\nTotal operating expenses were $2.36 billion, up 3.5% from the year-ago quarter’s level.\nAdjusted operating income totaled $1.15 billion, up 13.9% from that recorded a year ago. Adjusted operating margin was 21.9%, up 80 bps.\nFinancial Update\nStryker exited the first quarter with cash and cash equivalents of $2.41 billion compared with $3.05 billion in the fourth quarter of 2023.\nCumulative net cash provided by operating activities totaled $204 million compared with $445 million a year ago.\n2024 Guidance\nStryker raised its guidance for 2024. The company expects organic growth for total revenues in the range of 8.5-9.5% compared with the earlier guidance of 7.5-9.0%. The Zacks Consensus Estimate for total revenues is pegged at $22 billion. Based on the steady progress of the company’s pricing actions, it expects the full-year impact of price to be roughly flat.\nSYK expects adjusted EPS in the band of $11.85-$12.05, implying growth of 12.7% at the midpoint of the guided range. The Zacks Consensus Estimate for earnings is pegged at $11.86 per share. The company previously expected earnings in the range of $11.70-$12.00 per share.\nThe company expects unfavorable currency movement to hurt its top-line growth further in the first half of 2024. It also expects the same to hurt EPS by 5-10 cents.\nWrapping Up\nStryker exited first-quarter 2024 on a strong note, wherein both earnings and revenues beat their respective Zacks Consensus Estimate. The company witnessed strong performance in the U.S. market, notably in Instruments, Medical, Endoscopy, Trauma and Extremities, and Mako. Strong International sales also buoy optimism. SYK expects the momentum in the international market to accelerate in the rest of 2024.\nMoreover, the company is planning to grow its business through mergers and acquisitions in 2024. It has already acquired mfPHD, a leading provider of modular stainless steel wall systems, and SERF, a France-based joint replacement company.\nThe company is adopting several cost-cutting measures, including restructuring plans. These initiatives have led to a continued easing of certain cost pressures during the first quarter compared to the year-ago period. Moreover, positive pricing trends augur well for the company’s top-line growth. Stryker’s prospects in 2024 seem promising on the back of strong customer demand for its existing products as well as new launches. Its guidance for 2024 earnings and revenues appears encouraging.\nMoreover, the expansion in both gross and operating margins is reassuring. However, stiff competition in the MedTech space is a concern.\n\nStryker Corporation Price, Consensus and EPS Surprise\n\nStryker Corporation price-consensus-eps-surprise-chart | Stryker Corporation Quote\n\nZacks Rank\nStryker currently carries a Zacks Rank #4 (Sell).\nStocks to Consider\nSome better-ranked stocks in the broader medical space that have announced quarterly results are Align Technology, Inc. ALGN, Medpace MEDP and Boston Scientific Corporation BSX.\nAlign Technology, carrying a Zacks Rank of 2 (Buy) at present, reported first-quarter 2024 adjusted EPS of $2.14, which beat the Zacks Consensus Estimate by 8.1%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nRevenues of $997.4 million outpaced the consensus mark by 2.6%.\nAlign Technology has a long-term estimated growth rate of 6.9%. Its earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 5.9%.\nMedpace reported first-quarter 2024 adjusted EPS of $3.20, which beat the Zacks Consensus Estimate by 30.61%. Revenues of $511 million missed the Zacks Consensus Estimate by 0.3%. MEDP currently carries a Zacks Rank #2.\nMedpace has a long-term estimated growth rate of 17.9%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.83%.\nBoston Scientific reported first-quarter 2024 adjusted EPS of 56 cents, which beat the Zacks Consensus Estimate by 9.8%. Revenues of $3.86 billion surpassed the Zacks Consensus Estimate by 4.9%. It currently carries a Zacks Rank #2.\nBoston Scientific has a long-term estimated growth rate of 12.5%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.5%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nBoston Scientific Corporation (BSX) : Free Stock Analysis Report\nStryker Corporation (SYK) : Free Stock Analysis Report\nAlign Technology, Inc. (ALGN) : Free Stock Analysis Report\nMedpace Holdings, Inc. (MEDP) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[{"id":301342416343088,"gmtCreate":1714589344889,"gmtModify":1714589350710,"author":{"id":"4142551860919612","authorId":"4142551860919612","name":"nomadic_m","avatar":"https://community-static.tradeup.com/news/39af9fba1b299d25a4c88d224de77ac0","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"<a href=\"https://ttm.financial/S/SYK\">$Stryker(SYK)$ </a>beats estimates but plunged. next time pls don't schedule earnings +-1 day before Powell's speeches. his words alone can shoot down&nbsp;a dragon 🐲","listText":"<a href=\"https://ttm.financial/S/SYK\">$Stryker(SYK)$ </a>beats estimates but plunged. next time pls don't schedule earnings +-1 day before Powell's speeches. his words alone can shoot down&nbsp;a dragon 🐲","text":"$Stryker(SYK)$ beats estimates but plunged. next time pls don't schedule earnings +-1 day before Powell's speeches. his words alone can shoot down a dragon 🐲","images":[{"img":"https://community-static.tradeup.com/news/e1f2abf77a0f4c830fed267c565dee9d"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":3,"link":"https://ttm.financial/post/301342416343088","repostId":2432506451,"repostType":2,"repost":{"id":"2432506451","pubTimestamp":1714569180,"share":"https://www.laohu8.com/m/news/2432506451?lang=&edition=full","pubTime":"2024-05-01 21:13","market":"us","language":"en","title":"Stryker's (SYK) Q1 Earnings Beat Estimates, Guidance Raised","url":"https://stock-news.laohu8.com/highlight/detail?id=2432506451","media":"Zacks","summary":"Stryker Corporation SYK reported first-quarter 2024 adjusted earnings per share  of $2.50, which beat the Zacks Consensus Estimate of $2.35 by 6.4%. The bottom line also improved 16.8% year over year.GAAP EPS was $2.05, up 33.1% from the year-ago quarter’s level.SYK’s shares have risen 19.5% year to date compared with the industry's growth of 6.7%. The S&P 500 Index has increased 10.1% in the same period.Revenues totaled $5.24 billion, which beat the Zacks Consensus Estimate of $5.05 billion by 3.7%. The top line also improved 9.7% on a year-over-year basis and 10.2% at constant currency .Revenues in the United States amounted to $3.91 billion, up 11.4% from the prior-year quarter’s reported actuals. International sales increased to $1.33 billion and grew 4.9% year over year reportedly. The figure also rose 6.8%, excluding the negative impact of currency.MedSurg and Neurotechnology: This segment reported sales of $3 billion, up 11.5% year over year and 12.0% at cc. Sales growth was dri","content":"<html><body><p><strong>Stryker Corporation</strong> SYK reported first-quarter 2024 adjusted earnings per share (EPS) of $2.50, which beat the Zacks Consensus Estimate of $2.35 by 6.4%. The bottom line also improved 16.8% year over year.</p>\n<p>GAAP EPS was $2.05, up 33.1% from the year-ago quarter’s level.</p>\n<h3>Price Performance</h3>\n<p>SYK’s shares have risen 19.5% year to date compared with the industry's growth of 6.7%. The S&amp;P 500 Index has increased 10.1% in the same period.</p>\n<p><img src=\"https://s1.yimg.com/uu/api/res/1.2/yF3btlHV6GbxGeb88MES.Q--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/zacks.com/1262c0d934e84782f3bf66514b2a932c\"/><br/><span>Image Source: Zacks Investment Research</span><br/></p>\n<h3>Revenue Details</h3>\n<p>Revenues totaled $5.24 billion, which beat the Zacks Consensus Estimate of $5.05 billion by 3.7%. The top line also improved 9.7% on a year-over-year basis and 10.2% at constant currency (cc).</p>\n<h3>Revenues by Geography</h3>\n<p>Revenues in the United States amounted to $3.91 billion, up 11.4% from the prior-year quarter’s reported actuals. International sales increased to $1.33 billion and grew 4.9% year over year reportedly. The figure also rose 6.8%, excluding the negative impact of currency.</p>\n<h3>Segmental Analysis</h3>\n<p><strong>MedSurg and Neurotechnology: </strong>This segment reported sales of $3 billion, up 11.5% year over year and 12.0% at cc. Sales growth was driven by increased unit volume as well as higher prices.</p>\n<p><strong>Orthopedics and Spine: </strong>Sales in the segment amounted to $2.24 billion, up 7.5% year over year and 8% at cc. This growth was driven by increased unit volume, partially offset by lower prices.</p>\n<h3>Margins</h3>\n<p>Adjusted gross profit totaled $3.34 billion in the reported quarter, up 10.6% from the year-ago quarter’s level. Adjusted gross margin was 63.6%, up 40 basis points (bps).</p>\n<p>Total operating expenses were $2.36 billion, up 3.5% from the year-ago quarter’s level.</p>\n<p>Adjusted operating income totaled $1.15 billion, up 13.9% from that recorded a year ago. Adjusted operating margin was 21.9%, up 80 bps.</p>\n<h3>Financial Update</h3>\n<p>Stryker exited the first quarter with cash and cash equivalents of $2.41 billion compared with $3.05 billion in the fourth quarter of 2023.</p>\n<p>Cumulative net cash provided by operating activities totaled $204 million compared with $445 million a year ago.</p>\n<h3>2024 Guidance</h3>\n<p>Stryker raised its guidance for 2024. The company expects organic growth for total revenues in the range of 8.5-9.5% compared with the earlier guidance of 7.5-9.0%. The Zacks Consensus Estimate for total revenues is pegged at $22 billion. Based on the steady progress of the company’s pricing actions, it expects the full-year impact of price to be roughly flat.</p>\n<p>SYK expects adjusted EPS in the band of $11.85-$12.05, implying growth of 12.7% at the midpoint of the guided range. The Zacks Consensus Estimate for earnings is pegged at $11.86 per share. The company previously expected earnings in the range of $11.70-$12.00 per share.</p>\n<p>The company expects unfavorable currency movement to hurt its top-line growth further in the first half of 2024. It also expects the same to hurt EPS by 5-10 cents.</p>\n<h3>Wrapping Up</h3>\n<p>Stryker exited first-quarter 2024 on a strong note, wherein both earnings and revenues beat their respective Zacks Consensus Estimate. The company witnessed strong performance in the U.S. market, notably in Instruments, Medical, Endoscopy, Trauma and Extremities, and Mako. Strong International sales also buoy optimism. SYK expects the momentum in the international market to accelerate in the rest of 2024.</p>\n<p>Moreover, the company is planning to grow its business through mergers and acquisitions in 2024. It has already acquired mfPHD, a leading provider of modular stainless steel wall systems, and SERF, a France-based joint replacement company.</p>\n<p>The company is adopting several cost-cutting measures, including restructuring plans. These initiatives have led to a continued easing of certain cost pressures during the first quarter compared to the year-ago period. Moreover, positive pricing trends augur well for the company’s top-line growth. Stryker’s prospects in 2024 seem promising on the back of strong customer demand for its existing products as well as new launches. Its guidance for 2024 earnings and revenues appears encouraging.</p>\n<p>Moreover, the expansion in both gross and operating margins is reassuring. However, stiff competition in the MedTech space is a concern.</p>\n<div>\n<h3>Stryker Corporation Price, Consensus and EPS Surprise</h3>\n<img height=\"265\" src=\"https://s.yimg.com/uu/api/res/1.2/fp.GiFEAEaBAbC3K9b2llA--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/zacks.com/c5e1c837000652b27361c9d2e7e7e1a4\" title=\"\" width=\"587\"/>\n<p>Stryker Corporation price-consensus-eps-surprise-chart | Stryker Corporation Quote</p>\n</div>\n<h3>Zacks Rank</h3>\n<p>Stryker currently carries a Zacks Rank #4 (Sell).</p>\n<h3>Stocks to Consider</h3>\n<p>Some better-ranked stocks in the broader medical space that have announced quarterly results are <strong>Align Technology, Inc. </strong>ALGN, <strong>Medpace</strong> MEDP and <strong>Boston Scientific Corporation</strong> BSX.</p>\n<p>Align Technology, carrying a Zacks Rank of 2 (Buy) at present, reported first-quarter 2024 adjusted EPS of $2.14, which beat the Zacks Consensus Estimate by 8.1%. You can see <strong>the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.</strong></p>\n<p>Revenues of $997.4 million outpaced the consensus mark by 2.6%.</p>\n<p>Align Technology has a long-term estimated growth rate of 6.9%. Its earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 5.9%.</p>\n<p>Medpace reported first-quarter 2024 adjusted EPS of $3.20, which beat the Zacks Consensus Estimate by 30.61%. Revenues of $511 million missed the Zacks Consensus Estimate by 0.3%. MEDP currently carries a Zacks Rank #2.</p>\n<p>Medpace has a long-term estimated growth rate of 17.9%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.83%.</p>\n<p>Boston Scientific reported first-quarter 2024 adjusted EPS of 56 cents, which beat the Zacks Consensus Estimate by 9.8%. Revenues of $3.86 billion surpassed the Zacks Consensus Estimate by 4.9%. It currently carries a Zacks Rank #2.</p>\n<p>Boston Scientific has a long-term estimated growth rate of 12.5%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.5%.</p>\n<p>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report</p>\n<p>Boston Scientific Corporation (BSX) : Free Stock Analysis Report</p>\n<p>Stryker Corporation (SYK) : Free Stock Analysis Report</p>\n<p>Align Technology, Inc. (ALGN) : Free Stock Analysis Report</p>\n<p>Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report</p>\n<p>To read this article on Zacks.com click here.</p>\n<p>Zacks Investment Research</p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stryker's (SYK) Q1 Earnings Beat Estimates, Guidance Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStryker's (SYK) Q1 Earnings Beat Estimates, Guidance Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-01 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/strykers-syk-q1-earnings-beat-131300980.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stryker Corporation SYK reported first-quarter 2024 adjusted earnings per share (EPS) of $2.50, which beat the Zacks Consensus Estimate of $2.35 by 6.4%. The bottom line also improved 16.8% year over ...</p>\n\n<a href=\"https://finance.yahoo.com/news/strykers-syk-q1-earnings-beat-131300980.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/1VKaor.8d9bYcvO1nyOeow--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f6206b1433a2040570d7364e7915d0b5","relate_stocks":{"SYK":"史赛克"},"source_url":"https://finance.yahoo.com/news/strykers-syk-q1-earnings-beat-131300980.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2432506451","content_text":"Stryker Corporation SYK reported first-quarter 2024 adjusted earnings per share (EPS) of $2.50, which beat the Zacks Consensus Estimate of $2.35 by 6.4%. The bottom line also improved 16.8% year over year.\nGAAP EPS was $2.05, up 33.1% from the year-ago quarter’s level.\nPrice Performance\nSYK’s shares have risen 19.5% year to date compared with the industry's growth of 6.7%. The S&P 500 Index has increased 10.1% in the same period.\nImage Source: Zacks Investment Research\nRevenue Details\nRevenues totaled $5.24 billion, which beat the Zacks Consensus Estimate of $5.05 billion by 3.7%. The top line also improved 9.7% on a year-over-year basis and 10.2% at constant currency (cc).\nRevenues by Geography\nRevenues in the United States amounted to $3.91 billion, up 11.4% from the prior-year quarter’s reported actuals. International sales increased to $1.33 billion and grew 4.9% year over year reportedly. The figure also rose 6.8%, excluding the negative impact of currency.\nSegmental Analysis\nMedSurg and Neurotechnology: This segment reported sales of $3 billion, up 11.5% year over year and 12.0% at cc. Sales growth was driven by increased unit volume as well as higher prices.\nOrthopedics and Spine: Sales in the segment amounted to $2.24 billion, up 7.5% year over year and 8% at cc. This growth was driven by increased unit volume, partially offset by lower prices.\nMargins\nAdjusted gross profit totaled $3.34 billion in the reported quarter, up 10.6% from the year-ago quarter’s level. Adjusted gross margin was 63.6%, up 40 basis points (bps).\nTotal operating expenses were $2.36 billion, up 3.5% from the year-ago quarter’s level.\nAdjusted operating income totaled $1.15 billion, up 13.9% from that recorded a year ago. Adjusted operating margin was 21.9%, up 80 bps.\nFinancial Update\nStryker exited the first quarter with cash and cash equivalents of $2.41 billion compared with $3.05 billion in the fourth quarter of 2023.\nCumulative net cash provided by operating activities totaled $204 million compared with $445 million a year ago.\n2024 Guidance\nStryker raised its guidance for 2024. The company expects organic growth for total revenues in the range of 8.5-9.5% compared with the earlier guidance of 7.5-9.0%. The Zacks Consensus Estimate for total revenues is pegged at $22 billion. Based on the steady progress of the company’s pricing actions, it expects the full-year impact of price to be roughly flat.\nSYK expects adjusted EPS in the band of $11.85-$12.05, implying growth of 12.7% at the midpoint of the guided range. The Zacks Consensus Estimate for earnings is pegged at $11.86 per share. The company previously expected earnings in the range of $11.70-$12.00 per share.\nThe company expects unfavorable currency movement to hurt its top-line growth further in the first half of 2024. It also expects the same to hurt EPS by 5-10 cents.\nWrapping Up\nStryker exited first-quarter 2024 on a strong note, wherein both earnings and revenues beat their respective Zacks Consensus Estimate. The company witnessed strong performance in the U.S. market, notably in Instruments, Medical, Endoscopy, Trauma and Extremities, and Mako. Strong International sales also buoy optimism. SYK expects the momentum in the international market to accelerate in the rest of 2024.\nMoreover, the company is planning to grow its business through mergers and acquisitions in 2024. It has already acquired mfPHD, a leading provider of modular stainless steel wall systems, and SERF, a France-based joint replacement company.\nThe company is adopting several cost-cutting measures, including restructuring plans. These initiatives have led to a continued easing of certain cost pressures during the first quarter compared to the year-ago period. Moreover, positive pricing trends augur well for the company’s top-line growth. Stryker’s prospects in 2024 seem promising on the back of strong customer demand for its existing products as well as new launches. Its guidance for 2024 earnings and revenues appears encouraging.\nMoreover, the expansion in both gross and operating margins is reassuring. However, stiff competition in the MedTech space is a concern.\n\nStryker Corporation Price, Consensus and EPS Surprise\n\nStryker Corporation price-consensus-eps-surprise-chart | Stryker Corporation Quote\n\nZacks Rank\nStryker currently carries a Zacks Rank #4 (Sell).\nStocks to Consider\nSome better-ranked stocks in the broader medical space that have announced quarterly results are Align Technology, Inc. ALGN, Medpace MEDP and Boston Scientific Corporation BSX.\nAlign Technology, carrying a Zacks Rank of 2 (Buy) at present, reported first-quarter 2024 adjusted EPS of $2.14, which beat the Zacks Consensus Estimate by 8.1%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nRevenues of $997.4 million outpaced the consensus mark by 2.6%.\nAlign Technology has a long-term estimated growth rate of 6.9%. Its earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 5.9%.\nMedpace reported first-quarter 2024 adjusted EPS of $3.20, which beat the Zacks Consensus Estimate by 30.61%. Revenues of $511 million missed the Zacks Consensus Estimate by 0.3%. MEDP currently carries a Zacks Rank #2.\nMedpace has a long-term estimated growth rate of 17.9%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.83%.\nBoston Scientific reported first-quarter 2024 adjusted EPS of 56 cents, which beat the Zacks Consensus Estimate by 9.8%. Revenues of $3.86 billion surpassed the Zacks Consensus Estimate by 4.9%. It currently carries a Zacks Rank #2.\nBoston Scientific has a long-term estimated growth rate of 12.5%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.5%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nBoston Scientific Corporation (BSX) : Free Stock Analysis Report\nStryker Corporation (SYK) : Free Stock Analysis Report\nAlign Technology, Inc. (ALGN) : Free Stock Analysis Report\nMedpace Holdings, Inc. (MEDP) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}